一项多omics研究揭示了Linderae Radix水提取物对刺激性肠综合征 (IBS-D) 的治疗效果
Linqi Ouyang1, Tao Liu2, Yang He2
1First Hospital, Hunan University of Chinese Medicine, 95 Shaoshan Road, Changsha, Hunan, 410007, PR China; School of Pharmacy, Hunan University of Chinese Medicine, 300 Xueshi Road, Changsha, Hunan, 410208, PR China.
Journal of ethnopharmacology
|March 22, 2024
概括
Linderae Radix水提取物 (LRWE) 通过恢复肠道微生物群平衡和纠正代谢障碍,有效治疗腹占主导地位的刺激性肠综合征 (IBS-D). 这项研究确定了特定的细菌和代谢物作为IBS-D的潜在治疗点.
科学领域:
- 胃肠病学 胃肠病学
- 微生物组研究 微生物组研究
- 代谢学 代谢学 代谢学
背景情况:
- 林德拉根 (Linderae Radix,Lindera aggregata (Sims) Kosterm) 是一种传统的中医药,用于治疗胃肠道疾病.
- 以前的研究表明,林德雷雷迪克斯水提取物 (LRWE) 在治疗腹占主导地位的刺激性肠综合征 (IBS-D) 中具有有效性.
- 对于IBS-D,LRWE的确切治疗机制尚不清楚.
研究的目的:
- 用多omics技术阐明IBS-D中LRWE的治疗机制.
- 在IBS-D大鼠模型中研究LRWE对肠道微生物群和血清代谢学的影响.
- 根据微生物群和代谢物改变,确定IBS-D的潜在治疗点.
主要方法:
- 在IBS-D大鼠模型中结合了16S rRNA基因测序和LC-MS代谢学.
- 用于LRWE评估其对肠道微生物群组成和血清代谢物的影响.
- 利用斯皮尔曼相关性分析将肠道微生物群和代谢物概况联系起来.
主要成果:
- LRWE显著改善了IBS-D的症状,包括腹,内脏过敏和肠道炎症.
- 通过减少Patescibacteria和Candidatus Saccharimonas,并增加Jeotgalicoccus,LRWE调节了肠道微生物群.
- 鉴定了16种与氧酸/二氧酸和氨酸/甲氨酸代谢相关的不同血清代谢物,与微生物群变化相关.
结论:
- 通过重新平衡肠道微生物群和纠正代谢失调,LRWE证明了对IBS-D的全面治疗效果.
- 特定的细菌种群 (例如Jeotgalicoccus) 和代谢途径被确定为IBS-D的潜在治疗标.
- 这种多学科的方法为LRWE在IBS-D治疗中的有效性提供了机制性的见解.
相关概念视频
Drugs for Treatment of Constipation-Predominant IBS
162
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
162
Drugs for Treatment of Diarrhea-Predominant IBS
166
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
166
Irritable Bowel Syndrome I: Introduction
272
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
272
Irritable Bowel Syndrome III: Medical and Nursing Management
201
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
201
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
159
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
159
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
331
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
331


